PasitheaLogo.png
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
November 09, 2023 07:59 ET | Pasithea
Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS
22157.jpg
2022 TYSABRI (Natalizumab) Report: A Recombinant Humanized IgG4 Monoclonal Antibody Produced in Murine Myeloma Cells - Drug Insight and Market Forecasts to 2032
December 22, 2022 06:03 ET | Research and Markets
Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "TYSABRI (Natalizumab), Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering."TYSABRI (Natalizumab),...
Biogen_Logo_Standard-rgb_R.jpg
New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
September 12, 2019 05:00 ET | Biogen Inc.
Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data...
Biogen_Logo_Standard-rgb_R.jpg
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
May 01, 2019 07:30 ET | Biogen Inc.
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...
Biogen_Logo_Standard-rgb_R.jpg
First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
January 03, 2019 07:30 ET | Biogen Inc.
Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been...